Innoviva, Inc.(INVA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #186 of 2,961 stocksTOP 10%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in INVA
Events flagged as statistical outliers against INVA's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-05
INVA quality score dropped 25 points (75→50) on a new filing
View source filing →
INVA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Innoviva, Inc. (INVA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INVA at 71.4/100 on a 32-signal composite quality model, placing it at rank #186 of 2,961 stocks — the top 10% of the AI-ranked universe. INVA scores in the top quartile across profitability (97.4), free cash flow (92.4), balance sheet strength (89.6). Areas of concern include institutional flow (25.6) and revenue scale (34.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Innoviva, Inc. reports quarterly revenue of $119.6M, net income of $-83.4M, an operating margin of 42.5%. Top institutional holders of INVA by reported 13-F value include BlackRock, DIMENSIONAL FUND ADVISORS, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. INVA trades on the Nasdaq exchange and files with the SEC under CIK 1080014. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Innoviva, Inc. directly from SEC EDGAR. Innoviva, Inc.'s 13F Pro composite quality score has ranged between 51 and 76 since 2021, currently 71.4 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
What's Driving INVA's Business? Latest 10-Q Breakdown
✓ 36/36 datapoints verifiedAI-extracted from Innoviva, Inc.'s 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Total revenue grew 19% YoY to $119.6M as net product sales surged 46%, but a net loss of $83.4M resulted from a $131.8M unrealized loss on the Armata equity stake.
Biggest Revenue Drivers
Decrease driven by lower net sales due to pricing pressures in the United States
Higher sales volume from strategic commercialization efforts, led by XACDURO and GIAPREZA growth
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q2 2026
$119.6M
Net Income
Q2 2026
$-83.4M
Free Cash Flow
Q2 2026
$51.5M
Operating Margin
Q2 2026
42.5%
ROIC
Q2 2026
13.6%
D/E Ratio
Q2 2026
0.21
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+14.7% YoYOperating Income
-1.9% YoYEPS (Diluted)
+816.7% YoYTotal Assets
+25.7% YoYTotal Debt
-42.5% YoYOp. Cash Flow
+4.4% YoYFree Cash Flow
+3.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $411.3M +14.7% | $358.7M +15.5% | $310.5M -6.3% | $331.3M -15.4% | $391.9M +16.4% | $336.8M |
| Operating Income | $163.7M -1.9% | $166.9M +46.5% | $113.9M | — | $375.1M +16.8% | $321.1M |
| EPS (Diluted) | $3.30 +816.7% | $0.36 -83.6% | $2.20 -7.2% | $2.37 -17.4% | $2.87 +42.1% | $2.02 |
| Total Assets | $1.64B +25.7% | $1.30B +4.6% | $1.24B +1.0% | $1.23B +32.9% | $926.4M -7.3% | $999.6M |
| Total Debt | $257.7M -42.5% | $448.3M +0.5% | $446.2M -17.4% | $540.4M +36.9% | $394.7M +2.4% | $385.5M |
| Operating Cash Flow | $196.9M +4.4% | $188.7M +33.8% | $141.1M -30.1% | $201.7M -44.6% | $363.8M +16.2% | $313.1M |
| Free Cash Flow | $195.8M +3.9% | $188.4M +34.0% | $140.7M -30.3% | $201.7M -44.6% | $363.8M +16.2% | $313.1M |
Get alerted when INVA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Innoviva, Inc. including:
Top Institutional Holders of INVA
BlackRock, Inc.
$262.4M11,555,209 shDIMENSIONAL FUND ADVISORS LP
$102.1M4,494,053 shVANGUARD PORTFOLIO MANAGEMENT LLC
$95.8M4,220,273 shRENAISSANCE TECHNOLOGIES LLC
$91.7M4,036,532 shSTATE STREET CORP
$74.2M3,268,004 shVANGUARD CAPITAL MANAGEMENT LLC
$71.7M3,158,053 shMILLENNIUM MANAGEMENT LLC
$57.7M2,541,109 shCAMDEN ASSET MANAGEMENT L P /CA
$52.5M49,052,000 shGEODE CAPITAL MANAGEMENT, LLC
$47.1M2,074,709 shWOLVERINE ASSET MANAGEMENT LLC
$46.3M42,990,000 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $262.4M | 11,555,209 |
| DIMENSIONAL FUND ADVISORS LP | $102.1M | 4,494,053 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $95.8M | 4,220,273 |
| RENAISSANCE TECHNOLOGIES LLC | $91.7M | 4,036,532 |
| STATE STREET CORP | $74.2M | 3,268,004 |
| VANGUARD CAPITAL MANAGEMENT LLC | $71.7M | 3,158,053 |
| MILLENNIUM MANAGEMENT LLC | $57.7M | 2,541,109 |
| CAMDEN ASSET MANAGEMENT L P /CA | $52.5M | 49,052,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $47.1M | 2,074,709 |
| WOLVERINE ASSET MANAGEMENT LLC | $46.3M | 42,990,000 |
Companies Similar to INVA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Harmony Biosciences Holdings, Inc.
LEMAITRE VASCULAR INC
CATALYST PHARMACEUTICALS, INC.
IRONWOOD PHARMACEUTICALS INC
RIGEL PHARMACEUTICALS INC
VERACYTE, INC.
ACADIA PHARMACEUTICALS INC
LivaNova PLC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put INVA on your watchlist
Track score changes the day Innoviva, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is INVA a good stock to buy?
13F Pro's AI-powered analysis of Innoviva, Inc. (INVA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INVA are available on the INVA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. INVA is classified as a small company.
Which hedge funds own INVA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INVA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Innoviva, Inc.'s investment landscape.